Cargando…

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

BACKGROUND AND PURPOSE: While the efficacy and safety of combined tiotropium and olodaterol in patients with COPD was established in a large clinical trial program, it is important to assess whether clinical data can be applied to geographic patient groups, particularly for East Asian patients who m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Chunxue, Ichinose, Masakazu, Lee, Sang Haak, Lee, Kwan Ho, Jöns, Olaf, Bothner, Ulrich, Zhao, Yihua, Buhl, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701005/ https://www.ncbi.nlm.nih.gov/pubmed/29200840 http://dx.doi.org/10.2147/COPD.S137719

Ejemplares similares

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies
por: Ferguson, Gary T., et al.
Publicado: (2020)

Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies
por: LaForce, Craig, et al.
Publicado: (2018)

Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(®) and OTEMTO(®) Studies
por: Buhl, Roland, et al.
Publicado: (2020)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
por: Sauer, Rüdiger, et al.
Publicado: (2016)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis
por: Ferguson, Gary T., et al.
Publicado: (2015)

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO(®) study
por: Minakata, Yoshiaki, et al.
Publicado: (2019)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Study Design of VESUTO(®): Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease
por: Ichinose, Masakazu, et al.
Publicado: (2017)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016)

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT(®) Study Protocol
por: Buhl, Roland, et al.
Publicado: (2020)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G.
Publicado: (2018)

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO(®) and OTEMTO(®) studies: a subgroup analysis by age
por: Ferguson, Gary T, et al.
Publicado: (2016)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
por: Lan, Ying, et al.
Publicado: (2023)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease
por: Aalbers, René, et al.
Publicado: (2015)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis
por: He, Jie, et al.
Publicado: (2020)

Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies
por: Ferguson, Gary T., et al.
Publicado: (2017)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis: Retraction
Publicado: (2020)

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
por: O'Donnell, Denis E., et al.
Publicado: (2017)

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

Smart watch-based coaching with tiotropium and olodaterol ameliorates physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2017)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
por: Miravitlles, Marc, et al.
Publicado: (2017)

First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
por: Takahashi, Koichiro, et al.
Publicado: (2020)

Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy
por: Carone, Mauro, et al.
Publicado: (2020)

Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease
por: Takahashi, Koichiro, et al.
Publicado: (2021)

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
por: Muruganandan, Sanjeevan, et al.
Publicado: (2015)

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study
por: Feldman, Gregory J., et al.
Publicado: (2017)

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
por: Maltais, François, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dnnf9r76k9cjiib8ckjpbeigrn